olivLaw · US equity research
uniQure N.V. QURE
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
uniQure N.V. is a gene therapy company developing single treatments aimed at potentially curative results for rare and devastating diseases, with a focus on Huntington's disease. In July 2026 the FDA agreed that a BLA submission under the accelerated approval pathway is reasonable, and the company expects to submit in the third quarter of 2026, a decisive milestone for its lead program.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, uniQure N.V. (QURE) stock was 23.03 USD (−3.52% on the day), with market capitalisation 1.6 bn USD, beta 1.03, 52-week range 9.03–51.05 USD. Latest reported quarter (Q3 2026): revenue of 5.2 m USD (+40.4% YoY), net income of -61.2 m USD, diluted EPS -0.88 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 38.4
- weak (30–45)
- Bollinger (20, 2)
- 20.51 – 25.25
- in the upper half of the band · %B 0.53 · band width 20.7%
- SMA 50 / 200
- 33.01 / 29.67
- mixed trend
- MACD (12, 26, 9)
- -2.11 / -2.95
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +1.0% | −1.1% | +2.1 pp | — |
| 3 months | −47.9% | −0.5% | −47.5 pp | — |
| 6 months | +0.9% | +4.4% | −3.5 pp | — |
| Year to date | −3.8% | +12.3% | −16.1 pp | — |
| 1 year | −24.3% | +13.5% | −37.9 pp | −9.2% |
| 3 years | +276.6% | +76.4% | +200.2 pp | +38.4% |
| 5 years | −34.6% | +63.7% | −98.3 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.2 m | 1.6 m | 5.3 m | 3.7 m | 5.6 m | 3.6 m | 5.8 m | 5.2 m |
| Cost of revenue | 619.0 k | 197.0 k | 656.0 k | 398.0 k | 435.0 k | 219.0 k | 350.0 k | 236.0 k |
| Research & development | 38.8 m | 36.1 m | 35.4 m | 34.4 m | 34.8 m | 29.2 m | 34.0 m | 35.5 m |
| SG&A | 11.4 m | 10.9 m | 13.5 m | 19.4 m | 21.6 m | 20.1 m | 17.4 m | 23.9 m |
| Operating income | -45.8 m | -39.3 m | -43.9 m | -51.0 m | -51.1 m | -45.7 m | -52.2 m | -53.0 m |
| Depreciation & amortisation | 4.4 m | 4.5 m | 3.6 m ≈ | 3.6 m ≈ | 3.0 m | 3.0 m | 4.9 m ≈ | 5.5 m ≈ |
| Interest expense | 14.9 m | 15.1 m | 15.6 m | 16.7 m | 14.6 m | 14.0 m | 14.4 m | 14.6 m |
| Pre-tax income | -72.4 m | -43.1 m | -37.3 m | -71.9 m | -41.0 m | -53.0 m | -79.2 m | -60.5 m |
| Income tax | 856.0 k | 496.0 k | 425.0 k | 8.6 m | -3.9 m | 488.0 k | 1.8 m | 676.0 k |
| Net income | -73.3 m | -43.6 m | -37.7 m | -80.5 m | -37.1 m | -53.5 m | -81.1 m | -61.2 m |
| Diluted EPS | -1.50 ≈ | -0.82 | -0.69 | -1.38 | -0.60 ≈ | -0.85 | -1.22 | -0.88 |
| Operating cash flow | -52.8 m | -44.1 m | -39.9 m ≈ | -16.4 m ≈ | -77.6 m | -38.2 m | -28.6 m ≈ | -47.8 m ≈ |
| Capex | 40.0 k | 126.0 k | 260.0 k ≈ | -66.0 k ≈ | 119.0 k | 140.0 k | 472.0 k ≈ | 11.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.3 m | 7.3 m | 37.5 m | 524.0 m | 106.5 m | 15.8 m | 27.1 m | 16.1 m |
| Revenue YoY | −13.9% | −35.5% | +415.2% | +1,296.8% | −79.7% | −85.1% | +71.2% | −40.6% |
| Net income | -83.3 m | -124.2 m | -125.0 m | 329.6 m | -126.8 m | -308.5 m | -239.6 m | -199.0 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | −138.5% | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -3.11 | -2.81 | 7.04 | -2.71 | -6.47 | -4.92 | -3.46 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | −138.5% | unavailable | unavailable | unavailable |
| net % | -738.2% | -1,705.8% | -333.3% | 62.9% | -119.1% | -1,947.1% | -883.4% | -1,236.0% |
| Free cash flow | -78.4 m | -104.3 m | -142.1 m | 270.5 m | -162.7 m | -153.1 m | -186.1 m | -178.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 80.2 m USD
- Financial debt
- 49.7 m USD
- Net debt
- -30.5 m USD
- Equity
- 198.9 m USD
- Total assets
- 824.9 m USD
- Debt / equity
- 0.25x
- Current ratio
- 10.43x
- ROE
- unavailable
- ROA
- -28.8%
- FCF margin
- -1,108.2%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 37.5 m | 524.0 m | 106.5 m | 15.8 m | 27.1 m | 16.1 m | SEC (XBRL)· 02 Mar 2026verified |
| Cost of revenue | 2.9 m | 25.0 m | 1.3 m | 65.0 k | 1.3 m | 1.7 m | SEC (XBRL)· 02 Mar 2026verified |
| Gross profit | 34.6 m ≈ | 499.0 m ≈ | 105.2 m ≈ | 15.8 m ≈ | 25.9 m ≈ | 14.4 m ≈ | SEC (XBRL)· 02 Mar 2026derived |
| Research & development | 122.4 m | 143.5 m | 197.6 m | 214.9 m | 143.8 m | 140.7 m | SEC (XBRL)· 02 Mar 2026verified |
| SG&A | 42.6 m | 56.3 m | 55.1 m | 74.6 m | 52.7 m | 65.5 m | SEC (XBRL)· 02 Mar 2026verified |
| Operating income | -125.4 m | 310.6 m | -143.2 m | -282.9 m | -184.3 m | -185.3 m | SEC (XBRL)· 02 Mar 2026verified |
| Depreciation & amortisation | 10.6 m | 7.3 m | 8.5 m | 11.9 m | 12.6 m | 14.8 m | SEC (XBRL)· 02 Mar 2026verified |
| EBITDA | -114.8 m ≈ | 317.9 m ≈ | -134.6 m ≈ | -271.0 m ≈ | -171.7 m ≈ | -170.6 m ≈ | SEC (XBRL)· 02 Mar 2026derived |
| Interest expense | 3.8 m | 7.5 m | 11.7 m | 41.6 m | 63.7 m | 62.0 m | SEC (XBRL)· 02 Mar 2026verified |
| Pre-tax income | -141.4 m | 332.8 m | -128.3 m | -306.6 m | -237.1 m | -193.3 m | SEC (XBRL)· 02 Mar 2026verified |
| Income tax | -16.4 m | 3.2 m | -1.5 m | 1.9 m | 2.4 m | 5.6 m | SEC (XBRL)· 02 Mar 2026verified |
| Net income | -125.0 m | 329.6 m | -126.8 m | -308.5 m | -239.6 m | -199.0 m | SEC (XBRL)· 02 Mar 2026verified |
| Diluted EPS | -2.81 | 7.04 | -2.71 | -6.47 | -4.92 | -3.46 | SEC (XBRL)· 02 Mar 2026verified |
| Weighted average diluted shares | 44.5 m | 46.8 m | 46.7 m | 47.7 m | 48.6 m | 57.5 m | SEC (XBRL)· 02 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 244.9 m | 556.3 m | 228.0 m | 241.4 m | 158.9 m | 80.2 m | SEC (XBRL)· 02 Mar 2026verified |
| Receivables | 6.6 m | — | — | — | — | 5.9 m | SEC (XBRL)· 05 May 2026verified |
| Inventories | — | — | 6.9 m | 12.0 m | — | — | SEC (XBRL)· 28 Feb 2024verified |
| Current assets | 258.9 m | 628.2 m | 476.8 m | 651.9 m | 390.3 m | 656.0 m | SEC (XBRL)· 02 Mar 2026verified |
| Property, plant & equipment, net | 32.3 m | 43.5 m | 50.5 m | 46.5 m | 20.4 m | 13.8 m | SEC (XBRL)· 02 Mar 2026verified |
| Goodwill | 542.0 k | 27.6 m | 25.6 m | 26.4 m | 22.4 m | 25.4 m | SEC (XBRL)· 02 Mar 2026verified |
| Intangibles (excl. goodwill) | 3.4 m | 62.7 m | 58.8 m | 60.5 m | 71.0 m | 72.8 m | SEC (XBRL)· 02 Mar 2026verified |
| Total assets | 340.4 m | 809.2 m | 705.0 m | 831.7 m | 556.5 m | 824.9 m | SEC (XBRL)· 02 Mar 2026verified |
| Accounts payable | 3.8 m | 2.5 m | 11.0 m | 6.6 m | 7.2 m | 5.2 m | SEC (XBRL)· 02 Mar 2026verified |
| Long-term debt | 35.6 m | 101.0 m | 102.8 m | 101.7 m | 51.3 m | 49.7 m | SEC (XBRL)· 02 Mar 2026verified |
| Current liabilities | 27.3 m | 36.8 m | 75.9 m | 73.7 m | 40.1 m | 62.9 m | SEC (XBRL)· 02 Mar 2026verified |
| Total liabilities | 96.5 m | 213.4 m | 229.0 m | 624.0 m | 563.3 m | 626.0 m | SEC (XBRL)· 02 Mar 2026verified |
| Equity | 243.9 m † | 595.8 m † | 476.0 m † | 207.7 m † | -6.8 m † | 198.9 m † | SEC (XBRL)· 02 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -134.8 m | 288.0 m | -145.1 m | -145.9 m | -182.7 m | -178.0 m | SEC (XBRL)· 02 Mar 2026verified |
| Capex | 7.3 m | 17.4 m | 17.7 m | 7.2 m | 3.4 m | 439.0 k | SEC (XBRL)· 02 Mar 2026verified |
| Free cash flow | -142.1 m ≈ | 270.5 m ≈ | -162.7 m ≈ | -153.1 m ≈ | -186.1 m ≈ | -178.4 m ≈ | SEC (XBRL)· 02 Mar 2026derived |
| Investing cash flow | -9.5 m | -67.4 m | -182.7 m | -205.7 m | 163.0 m | -321.6 m | SEC (XBRL)· 02 Mar 2026verified |
| Financing cash flow | 7.4 m | 94.9 m | 1.4 m | 362.7 m | -59.5 m | 415.4 m | SEC (XBRL)· 02 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.6 bn USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -1,154.8% | 12 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -46.7% | 0 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -3.5x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 11.5x | 100 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -11.9% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial12/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
uniQure N.V. (QURE). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 16.1 m USD in 2025; YoY growth -40.6%; net margin -1,154.8%; ROE -89.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 11.5x
What contradicts it
- Net margin: -1,154.8%
- Revenue CAGR 3Y: -46.7%
- Interest coverage: -3.5x
- FCF yield: -11.9%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| IONSIonis Pharmaceuticals, Inc. | 6.7 bn | — | -105.5% | -64.7% | +33.8% | −51% / −19% |
| AMRNAmarin Corp Plc\uk | 5.2 bn | — | -4.2% | -10.9% | −6.5% | −23% / −21% |
| IDYAIDEAYA Biosciences, Inc. | 3.1 bn | — | -38.5% | -1,149.6% | +3,024.4% | −9% / +3% |
| RADXRadiopharm Theranostics Limited | 3.1 bn | — | -109.2% | -1,055.3% | +1,114.3% | −81% / unavailable |
| AUPHAurinia Pharmaceuticals Inc. | 2.3 bn | 7.5 | 61.4% | 97.7% | +20.4% | +6% / +98% |
| QUREuniQure N.V. | 1.6 bn | — | -89.0% | -1,154.8% | −40.6% | −24% / +277% |
| URGNUroGen Pharma Ltd. | 1.4 bn | — | — | -26.3% | +21.4% | −0% / +118% |
1- and 3-year price returns: for QURE from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
In brief
uniQure N.V. is a gene therapy company developing single treatments aimed at potentially curative results for rare and devastating diseases, with a focus on Huntington's disease. In July 2026 the FDA agreed that a BLA submission under the accelerated approval pathway is reasonable, and the company expects to submit in the third quarter of 2026, a decisive milestone for its lead program 3.
SWOT
Strengths
- The company has a proprietary gene therapy platform and a pioneering position in Huntington's disease, with multiple regulatory designations 1.
- The balance sheet was strengthened by the June 2026 offering, extending the funding runway 3.
- Longer-term data show favourable effects at the high dose, with a manageable safety profile in Phase I/II studies 12.
Weaknesses
Opportunities
Risks
- Rejection of the external-control routehigh
The FDA has indicated that data from the Phase I/II studies are not sufficient alone for a marketing application, and alignment on the confirmatory study remains under discussion 12.
- Safety of gene therapiesmedium
Serious adverse events and dose-limiting toxicities in other programmes have been reported and could lead to further clinical pauses 13.
- Financing and dilutionmedium
Share issuances and the floating-rate loan could reduce value for shareholders or limit financing options 12.
- Manufacturing and enrolment delayslow
Delays in patient enrolment or manufacturing could lengthen the clinical timeline 1.
Investment thesis
What would need to be true (bull case)
What would break the thesis
- If the FDA requires a randomised study with a standard-of-care control, submission and approval could be considerably delayed 12.
- Revenues remain low and large net losses could test investor patience if progress stalls 13.
- Liver events and other reactions in the Fabry and ALS programmes could extend clinical pauses and weigh on the portfolio outlook 13.
What to watch
- Completion of AMT-260 second cohort enrolment and updated Phase I/IIa resultsfirst half 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (04 Nov 2026 · results), 10-Q (04 Nov 2026).
The business
uniQure N.V. presents itself as a leader in gene therapy, seeking to deliver single treatments with potentially curative results to patients with rare or devastating diseases 1. Its pipeline includes clinical candidates for Huntington's disease, refractory mesial temporal lobe epilepsy, Fabry disease and SOD1 amyotrophic lateral sclerosis 1. Cash and investments were 622.5 million USD on 31 December 2025 and 810.3 million USD on 30 June 2026 13.
Revenues are modest and come mainly from licences and collaborations rather than sales of own products 13. The net loss remains significant, so equity offerings and loans are a central part of the funding model 12. The company says its current resources should fund projected operating expenses into 2030 3.
Segments
Refractory mesial temporal lobe epilepsy (AMT-260)
The programme is in the Phase I/IIa GenTLE study in the U.S. Preliminary six-month data in the low-dose cohort showed meaningful seizure reductions in three of six patients, with no related serious adverse events reported 3. Enrolment of the second cohort is expected to complete in the third quarter of 2026 3.
Market context
Refractory temporal lobe epilepsy has a sizeable population, and patients with mesial lesions are rarely treated surgically 1. This context could support interest in local therapies such as AMT-260 if clinical data are confirmed 1. The Fabry and SOD1 ALS markets are narrower and remain at early clinical stages 1.
Trends
- Stricter regulation of external-control datamixed
The FDA indicated that data compared with an external control are not sufficient on their own, which could lengthen the approval timeline if alignment does not hold 12. However, the July 2026 agreement on the accelerated route signals regulatory openness 3.
- Access to capital and loansmixed
Recent public offerings and the 175 million USD Hercules loan support funding, but interest costs are high 123. If approval is delayed, pressure on financing could increase.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapySTAT News · 01 Oct 2026 · EN
- STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four yearsSTAT News · 29 Sept 2026 · EN
- STAT+: What to expect from UniQure’s upcoming Huntington’s gene therapy readoutSTAT News · 10 Sept 2026 · EN
- UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agencyCNBC World · 17 Jun 2026 · EN
- UniQure Shares Soar After FDA Reversal on Its Huntington’s TherapyBloomberg Markets · 17 Jun 2026 · EN
The latest news item in our archive is from 01 Oct 2026; the newest SEC filing is from 04 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report04 Nov 2026
- Current report04 Nov 2026Results of operations · Financial statements and exhibits
- Current report02 Nov 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report29 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report02 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report29 Jul 2026
- Current report29 Jul 2026Results of operations · Financial statements and exhibits
- Current report24 Jun 2026Material agreement · Other events · Financial statements and exhibits
- Current report22 Jun 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report17 Jun 2026Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / uniQure N.V. · 02 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / uniQure N.V. · 29 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / uniQure N.V. · 29 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.